Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Obesity (Silver Spring). 2014 Jun 24;22(10):2105–2108. doi: 10.1002/oby.20813

Table 1.

Parameter values quantifying the placebo-subtracted drug effect on changes in metabolizable energy intake.

Drug pearly [kcal/d] τ [d] plate [kcal/d] R2 Duration [weeks] Dose [mg] Ref.
Dexfenfluramine 426 35 −39 0.73 52 15 (18)
Diethylpropion 512 175 95 0.9 52 75 (21)
Exenatide 130 72 51 0.43 30 0.005 (12)
241 83 104 0.93 30 0.01 (12)
Fenproporex 438 105 96 0.84 52 25 (21)
Fluoxetine 323 59 −117 0.92 52 20 (21)
Liraglutide 823 17 225 0.72 52 3 (11)
676 45 143 0.86 52 2.4 (11)
725 26 157 0.76 52 1.8 (11)
598 18 36 0.86 52 1.2 (11)
Lorcaserin 430 141 39 0.86 104 10 (20)
Mazindol 570 77 49 0.98 52 2 (21)
Naltrexone + Bupropion 458 69 76 0.82 56 N/B
32/360		 (16)
Orlistat 240 273 46 0.99 208 120 (22)
149 499 −2 0.97 104 60 (15)
251 429 −30 0.99 104 120 (15)
Phentermine + Fenfluramine 882 53 571 0.87 34 Phen/Fen
15/60		 (23)
Phentermine + Topiramate 343 115 109 0.82 56 PHEN/TPM
3.75/23		 (10)
859 113 259 0.96 56 PHEN/TPM
15/92		 (10)
545 85 227 0.98 56 PHEN/TPM
7.5/46		 (13)
749 104 268 0.98 56 PHEN/TPM
15/92		 (13)
702 57 170 0.79 108 PHEN/TPM
7.5/46		 (14)
945 78 189 0.86 108 PHEN/TPM
15/92		 (14)
Rimonabant 140 128 −18 0.82 52 5 (19)
466 125 38 0.93 52 20 (19)
Sibutramine 202 105 41 0.99 260 10 (17)
502 87 38 0.96 48 15 (24)
775 54 161 0.96 52 15 (21)